BIYELA - Bexsero Immunisation in Young Women in Africa

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

1,100

Participants

Timeline

Start Date

August 14, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

January 31, 2027

Conditions
GonorrheaGonorrhea of PharynxGonorrhea of AnusGonorrhea of Cervix
Interventions
BIOLOGICAL

Bexsero

Administered as an IM injection by 0.5-mL single-dose syringe at enrollment (Visit 1) and 2 months post-enrollment (Visit 3).

BIOLOGICAL

Placebo

Administered as an IM injection by 0.5-mL single-dose syringe at enrollment (Visit 1) and 2 months post-enrollment (Visit 3).

Trial Locations (5)

Unknown

Desmond Tutu Health Foundation - Emavundleni Research Centre, Cape Town

Desmond Tutu Health Foundation - Masiphumulele Site, Cape Town

Khayelitsha Vuka Research Clinic, Cape Town

Wits RHI Ward 21 Clinical Research Site, Johannesburg

Center for Community Based Research (CCBR), Pietermaritzburg

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

collaborator

University of Witwatersrand, South Africa

OTHER

lead

University of Washington

OTHER

NCT06446752 - BIYELA - Bexsero Immunisation in Young Women in Africa | Biotech Hunter | Biotech Hunter